| 作成者 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 本文言語 |
|
| 出版者 |
|
|
|
| 発行日 |
|
| 収録物名 |
|
| 巻 |
|
| 号 |
|
| 開始ページ |
|
| 終了ページ |
|
| 出版タイプ |
|
| アクセス権 |
|
| JaLC DOI |
|
| 関連DOI |
|
| 関連URI |
|
| 関連HDL |
|
| 概要 |
Purpose: Oxaliplatin,Irinotecan,5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries. Here,we investigated the efficacy and safety of FOLFOX/FOLFIRI... in Japanese colorectal cancer patients. Methods: FOLFOX4,modified FOLFOX6 and FOLFIRI was administered to a total of 23 patients with far advanced or recurrent colorectal cancer in our institute. Tumor response rate and toxicity were analyzed with these patients. Results: Partial response and stable disease was observed in 28.6% of patients, respectively. There was no therapy-related death. Neutropenia was observed in 12 cases (52.2%),anemia was in 12 cases (52.2%) and thrombocytopenia was in 6 cases (26.1%), respectively; among them, 9 patients (39.1%) experienced a Grade 3 of bone marrow suppression. Fatigue was observed in 8 cases (34.8%), nausea/vomiting was in 4 cases (17.4%), diarrhea was in 4 cases (17.4%) and neurotoxicity was in 8 cases (34.8%), respectively. All nonhematological toxicities were Grade 1 or 2. Conclusion : FOLFOX/FOLFIRI can contribute to efficacy and safety in cases of advanced colorectal cancer. In order to evaluate the long-term clinical results in Japanese patients,prospective controlled studies are urgently called for.
【目的】Oxaliplatin，Irinotecanを用いたFOLFOX/FOLFIRI は，欧米においては進行大腸癌に対する標準治療である．我々は日本人の進行大腸癌患者に対するFOLFOX/FOLFIRI の効果と安全性について検討した．【方法】当施設においてFOLFOX4，modified FOLFOX6，FOLFIRIが23人の高度進行，再発大腸癌患者に対して行われた．それらの腫瘍縮小効果，副作用について解析した．【結果】PR とSD はそれぞれ28.6%ずつに認めた．治療関連死は認めなかった．好中球減少は12人（52.2%），貧血は12人（52.2%），血小板減少は6人（26.1%），うちGrade3の骨髄抑制は9人（39.1%）に認めた．全身倦怠感は8人（34.8%），悪心，嘔吐は4人（17.4%），下痢は4人（17.4%），神経毒性は8人（34.8%）に認めた．すべての非血液毒性はGrade1か2であった．【結論】FOLFOX/FOLFIRI は高度進行，再発大腸癌患者に対して有効で，かつ安全に投与できると考えられた．日本人患者における長期成績を検証するための臨床試験が急務である．続きを見る
|
Mendeley出力
fam98-6_p253